From each FDA label

Do GLP-1s cause acid reflux?

Acid reflux is in the main trial table of 4 labels. The highest rate printed is 7% on Foundayo 17.2 mg (2% on placebo) and the lowest 4.7% on Saxenda 3 mg (1.7% on placebo). Separate trials, so not a ranking.

Read from each manufacturer's FDA label on DailyMed. The newest revision saying anything on this is Aug 27, 2026.

Rate against placebo

How often acid reflux happened in each medicine's trials

At the highest dose in each label's main table. Separate trials with different people, so compare each rate with its own placebo group, not with another medicine.

MedicineDoseOn itOn placeboDifferenceLabel
Foundayo17.2 mg7%2%+5 pointsDailyMed
Wegovy2.4 mg5%3%+2 pointsDailyMed
Zepbound15 mg5%2%+3 pointsDailyMed
Saxenda3 mg4.7%1.7%+3.0 pointsDailyMed
Word for word

What each label says about acid reflux

Sentences from each label's warnings and side effect sections. Only cross-references are removed.

Wegovy

  • The most frequently reported reactions were nausea (44% vs. 16%), vomiting (25% vs. 6%), and diarrhea (30% vs. 16%). Other reactions that occurred at a higher incidence among Wegovy injection-treated adult patients included dyspepsia, abdominal pain, abdominal distension, eructation, flatulence, gastroesophageal reflux disease, gastritis, hemorrhoids, and hiccups.
  • The most frequently reported reactions were nausea (42% vs. 18%), vomiting (36% vs. 10%), and diarrhea (22% vs. 19%). Other gastrointestinal-related reactions that occurred at a higher incidence than placebo among Wegovy injection-treated pediatric patients included abdominal pain, constipation, eructation, gastroesophageal reflux disease, dyspepsia, and flatulence.

Label revised Jun 18, 2026. DailyMed

Ozempic

  • In addition to the reactions in Table 1, the following gastrointestinal adverse reactions with a frequency of <5% were associated with Ozempic (frequencies listed, respectively, as: placebo; 0.5 mg; 1 mg): dyspepsia (1.9%, 3.5%, 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%).

Label revised Jun 1, 2026. DailyMed

Rybelsus and Ozempic tablets

  • In addition to the reactions in Table 2, the following gastrointestinal adverse reactions with a frequency of <5% occurred in semaglutide tablets -treated patients (frequencies listed, respectively, as 14 mg once daily, 7 mg once daily and placebo): abdominal distension (3%, 2% and 1%), dyspepsia (0.6%, 3%, 0.6%), eructation (2%, 0.6%, 0%,), flatulence (1%, 2%, 0%), gastroesophageal reflux disease (2%, 2%, 0.3%) and gastritis (2%, 2%, 0.8%).

Label revised Jan 30, 2026. DailyMed

Mounjaro

  • The following gastrointestinal adverse reactions were reported more frequently in Mounjaro-treated adult patients than placebo-treated patients (frequencies listed, respectively, as: placebo; 5 mg; 10 mg; 15 mg): eructation (0.4%, 3.0%, 2.5%, 3.3%), flatulence (0%, 1.3%, 2.5%, 2.9%), gastroesophageal reflux disease (0.4%, 1.7%, 2.5%, 1.7%), abdominal distension (0.4%, 0.4%, 2.9%, 0.8%).

Label revised Aug 27, 2026. DailyMed

Trulicity

  • The following GI adverse reactions were reported more frequently in Trulicity-treated patients than placebo -treated patients (frequencies listed, respectively, as: placebo; 0.75 mg; 1.5 mg): constipation (0.7%, 3.9%, 3.7%), flatulence (1.4%, 1.4%, 3.4%), abdominal distension (0.7%, 2.9%, 2.3%), gastroesophageal reflux disease (0.5%, 1.7%, 2.0%), and eructation (0.2%, 0.6%, 1.6%).

Label revised Jun 16, 2026. DailyMed

Saxenda

  • The percentage of patients reporting nausea declined as treatment continued. Other common adverse reactions that occurred at a higher incidence among Saxenda-treated patients included diarrhea, constipation, vomiting, dyspepsia, abdominal pain, dry mouth, gastritis, gastroesophageal reflux disease, flatulence, eructation and abdominal distension.

Label revised Feb 25, 2026. DailyMed

Zepbound, Foundayo, Victoza, Byetta: no finding on this in the sections read here.

Not from trials

Reports to FDA about acid reflux

Counts of voluntary reports from patients and doctors. They cannot show that a medicine caused anything and cannot give a rate, and a brand used by more people draws more reports.

MedicineReports namingAll reports on it
ZepboundAcid reflux: 1,02980,835
OzempicAcid reflux: 82470,863
MounjaroAcid reflux: 75797,440
TrulicityAcid reflux: 70787,279
ByettaAcid reflux: 64952,087
VictozaAcid reflux: 47741,462
WegovyAcid reflux: 35925,993
SaxendaAcid reflux: 1097,270
Rybelsus and Ozempic tabletsAcid reflux: 917,758
FoundayoAcid reflux: 663,050

Counted through openFDA from FDA's Adverse Event Reporting System, refreshed weekly. One report can name several terms.

Updated automatically

Latest FDA label updates

Written from each source's own record as it changes. Every change on GLPcompare

Questions

Acid reflux on a GLP-1: common questions

Which GLP-1 causes the most acid reflux?

No trial here ranks them. By the rates each label prints, Foundayo 17.2 mg is highest at 7% (placebo 2%) and Saxenda 3 mg lowest at 4.7% (placebo 1.7%). These come from separate trials with different people and doses, so compare each to its own placebo group.

Does Foundayo cause acid reflux?

In its FDA label, 7% of people taking Foundayo 17.2 mg reported acid reflux, against 2% on placebo.

Does Wegovy cause acid reflux?

In its FDA label, 5% of people taking Wegovy 2.4 mg reported acid reflux, against 3% on placebo.

Does Zepbound cause acid reflux?

In its FDA label, 5% of people taking Zepbound 15 mg reported acid reflux, against 2% on placebo.

Does Saxenda cause acid reflux?

In its FDA label, 4.7% of people taking Saxenda 3 mg reported acid reflux, against 1.7% on placebo.

Other side effects

Trial rates describe groups, not what one person will feel. Talk to your clinician before starting, stopping or changing a medicine.

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.